Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study

Figures & data

Figure 1 Study flow chart.

Table 1 Cohort characteristics at entry into the study

Variable	Mean	±SD	Minimum	Maximum
Age (years)	54	9	39	73
Weight (kg)	71.1	14.1	42.0	107.8
Height (cm)	156	9.0	145	173
BMI (kg/m^2)
Males (n=2)	26.48	5.64	22.49	30.46
Females (n=20)	29.93	6.71	19.05	46.88
Fasting blood glucose (mmol/l)	15.4	3.8	9.9	21.8
Fasting blood insulin (μU/ml)	13.9	6.9	3.0	24.7
Glycosylated hemoglobin (%)	12.2	3.8	8.1	18.5
Cholesterol (mmol/L)	5.8	1.2	4.0	8.2
Low-density lipoprotein cholesterol (mmol/L)	3.9	1.0	2.2	5.9
High-density lipoprotein cholesterol (mmol/L)	1.1	0.3	0.8	1.8
Triglycerides (mmol/L)	1.6	0.9	0.5	4.0
Alanine transferase (U/L)	25.0	12.6	10.0	59.0
Creatinine (μmol/L)	64.1	10.4	48.0	91.0
Sex	Females, 20 (91%)	Males, 2 (9%)
Duration of diabetes (years)	0–5	n=8
	6–10	n=6
	>10	n=8

Abbreviations: BMI, body mass index; SD, standard deviation.

Figure 2 Mean plasma glibenclamide concentration versus dose.

Figure 3 Mean blood glucose concentration versus dose of glibenclamide.

Figure 4 Mean insulin concentration versus dose of glibenclamide.